Statement regarding mailing of interim report

PROTEOME SCIENCES plc                             

                                 PRESS RELEASE                                 

                       Interim Report to 30th June, 2007                       

 
8 October 2007.  The Directors of Proteome Sciences plc ("Proteome Sciences")
announce that copies of the Interim Report for the six months to the 30th June,
2007 were posted to shareholders on Friday 5th October, 2007.

                                     Ends                                      

Notes to editors:

 

Proteome Sciences plc applies high sensitivity proteomics to identify and
characterise differential protein expression in diseases for diagnostic,
prognostic and therapeutic applications.  It has discovered blood biomarkers
principally for stroke, vCJD, BSE, brain damage, solid organ transplant
rejection and Alzheimer's disease. The main focus of its research currently
addresses neurological, neurodegenerative, oncology and cardiovascular
conditions.

In addition to its own proprietary biomarkers, Proteome Sciences has developed
ProteoSHOP® (Proteome Sciences High Output Proteomics), a toolbox that offers
high sensitivity and high throughput gel and gel-free proprietary technologies
for the identification and validation of potential biomarkers and drug targets,
including specialisation in membrane proteins and protein phosphorylation. 

The Company has developed a range of specialist reagents to improve the
performance and quantitation of protein separation and characterisation with
mass spectrometry, bioinformatics, statistics and pattern recognition. These
include Sensitizer®, PST®, qPST™ and TMT®.  Proteome Sciences has patent
allowances in the major global jurisdictions for isobaric tandem mass tags (TMT
®) for the manufacture and use of any type of isobaric mass tags.

Commercialisation is actively pursued across the portfolio of the Company's
programmes and technologies with licensing deals signed in biomarkers for
Stroke and TSEs and for ProteoSHOP®.

Proteome Sciences has its headquarters in Cobham, Surrey in the UK and has
laboratories at Kings College Hospital, London and Frankfurt Innovations
Zentrum (FIZ), Frankfurt. It employs 32 full time scientists in addition to its
corporate and business development staff, and has collaborative research
agreements with leading academic institutes. The Company is listed on the
Alternative Investment Market.

For further information please visit www.proteomics.com.

Proteome Sciences plc

Christopher Pearce, Chief Executive Officer     James Malthouse, Finance Director
Email: [e-mail]        Email: [e-mail]
                                 Tel: [phone]                            

                                     Public Relations

IKON Associates                                 Coast Communications
Adrian Shaw                                     Matt Baldwin
Tel: [phone]                         Tel:[phone]
Mobile:[phone]                       Mobile:[phone]
Email: [e-mail]                Email: [e-mail]


Nominated Adviser
Landsbanki Securities (UK) Limited
Thilo Hoffman - Tel: [phone]